Vertex Pharmaceuticals Inc. (VRTX) said Tuesday that two Phase 3 studies of the triple combination of the next-generation corrector VX-659, Tezacaftor and Ivacaftor met the primary endpoint of improvement in lung function in people with cystic fibrosis or CF.
from RTT - Biotech https://ift.tt/2SdY9r2
via IFTTT
No comments:
Post a Comment